We are live on ! Find out more
ACM

ACT Capital Management Portfolio holdings

AUM $153M
This Fund
S&P 500
This Quarter Est. Return
+6.71%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$72.5M
AUM Growth
+$956K
Cap. Flow
+$1.31M
Cap. Flow %
1.81%
Top 10 Hldgs %
68.94%
Holding
88
New
10
Increased
5
Reduced
17
Closed
17

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$3.65M
2
XOM icon
ExxonMobil
XOM
+$2.26M
3
VTLE
Vital Energy
VTLE
+$1.5M
4
VRNA
Verona Pharma
VRNA
+$1.21M
5
FANG icon
Diamondback Energy
FANG
+$811K

Top Sells

Rank Stock Value
1
IDYA icon
IDEAYA Biosciences
IDYA
+$2.39M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$1.78M
3
ARWR icon
Arrowhead Research
ARWR
+$989K
4
LNTH icon
Lantheus
LNTH
+$852K
5
CF icon
CF Industries
CF
+$772K

Sector Composition

Rank Sector Weight
1 Healthcare 60.54%
2 Energy 29.19%
3 Technology 7.65%
4 Communication Services 1.77%
5 Industrials 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
YCBD.PRA
51
DELISTED
cbdMD, Inc. 8.0% Series A Cumulative Convertible Preferred Stock
YCBD.PRA
$77K 0.11%
22,000
– –
CLRB icon
52
Cellectar Biosciences
CLRB
$20.1M
$73K 0.1%
725
– –
ENLV icon
53
Enlivex Ltd
ENLV
$36.7M
$64K 0.09%
1,000
– –
SDPI
54
DELISTED
Superior Drilling Products Inc.
SDPI
$54K 0.07%
80,000
– –
CTSO icon
55
Cytosorbents Corp
CTSO
$24.2M
$48K 0.07%
35,000
– –
TCON
56
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$48K 0.07%
1,425
– –
OYST
57
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$48K 0.07%
8,500
– –
YALA
58
Yalla Group
YALA
$815M
$44K 0.06%
13,500
– –
SIOX
59
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$41K 0.06%
146,500
– –
PDSB icon
60
PDS Biotechnology
PDSB
$40.6M
$36K 0.05%
12,000
– –
SQZ
61
DELISTED
SQZ Biotechnologies Company
SQZ
$36K 0.05%
16,000
– –
CYT
62
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$29K 0.04%
15,000
– –
YCBD icon
63
cbdMD
YCBD
$6.19M
$28K 0.04%
347
– –
BLRX
64
BioLineRX
BLRX
$11.8M
$25K 0.03%
688
– –
TIL icon
65
Instil Bio
TIL
$49.2M
$24K 0.03%
250
– –
SYRS
66
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$23K 0.03%
3,499
-1
-0% -$8
ARAV
67
DELISTED
Aravive, Inc. Common Stock
ARAV
$15K 0.02%
18,777
– –
AIRS icon
68
AirSculpt Technologies
AIRS
$349M
$10K 0.01%
1,500
– –
RNAZ icon
69
TransCode Therapeutics
RNAZ
$4.5M
– –
0
– –
GTH
70
DELISTED
Genetron Holdings Limited ADS
GTH
$6K 0.01%
2,500
– –
ATRA icon
71
Atara Biotherapeutics
ATRA
$76.9M
$3K ﹤0.01%
36
-332
-90% -$37.3K
AMZN icon
72
Amazon
AMZN
$2.94T
– –
-1,000
Closed -$106K
AUPH icon
73
Aurinia Pharmaceuticals
AUPH
$1.95B
– –
-51,000
Closed -$513K
CF icon
74
CF Industries
CF
$17.9B
– –
-9,000
Closed -$772K
HSDT icon
75
Solana Company
HSDT
$100M
– –
-1
Closed -$42K
1 2
3
4

Similar funds

BCI
Blue Capital Inc Omaha, Nebraska $153M AUM 28.69% 1-Year Est. Return
APW
Atlantic Private Wealth Chapel Hill, North Carolina $153M AUM 15.75% 1-Year Est. Return
DAM
Doheny Asset Management Los Angeles, California $153M AUM 42.04% 1-Year Est. Return
BVC
Bright Valley Capital Hong Kong $153M AUM 16.24% 1-Year Est. Return
RHAM
Round Hill Asset Management Pasadena, California $153M AUM 6.67% 1-Year Est. Return
RFN
Redwood Financial Network Solon, Ohio $153M AUM 17.17% 1-Year Est. Return
SGM
Sellaronda Global Management New York $152M AUM 2.1% 1-Year Est. Return
HWM
Horizons Wealth Management Asheville, North Carolina $152M AUM 9.43% 1-Year Est. Return

ACT Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, ACT Capital Management held 88 positions worth $72.5M, up 1.3% from $71.5M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

ACT Capital Management's Q3 2022 filing shows 10 new, 5 increased, 17 reduced and 17 closed positions. Its largest new stake was Axsome Therapeutics: 73,000 shares worth $3.26M. The largest sale was IDEAYA Biosciences, an estimated $2.39M.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, down from 67% a quarter earlier, followed by Energy and Technology.

  • ACT Capital Management's largest Q3 2022 buy was Axsome Therapeutics: 73,000 shares worth $3.26M.
  • ACT Capital Management added most to ExxonMobil in Q3 2022, an estimated $2.26M increase.
  • ACT Capital Management's biggest Q3 2022 reduction was Arcturus Therapeutics, cutting an estimated $1.78M.
  • ACT Capital Management fully exited IDEAYA Biosciences in Q3 2022, selling an estimated $2.39M.
  • ACT Capital Management's ten largest holdings make up 69% of its $72.5M portfolio in Q3 2022.
  • ACT Capital Management opened 10 new positions and closed 17 in Q3 2022.
  • ACT Capital Management's portfolio value rose 1.3% quarter-over-quarter to $72.5M.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.